Next-generation stent technology is and will be bio-absorbable or bioresorbable. To gain a richer understanding of the current trends, I sat down with Craig Thompson, MD, who is SVP/CMO of Boston Scientific’s Interventional Cardiology. Dr. Thompson also provided insight behind the SYNERGY Coronary Stent's development.
China's course toward national development has placed healthcare reform front and center. An expanding middle class — with expanding global connectivity — is increasingly demanding congruency with Western healthcare standards. This two-part article outlines key challenges and opportunities resultant of China’s 13th Five-Year Plan and healthcare reform, starting with a look at domestic systems' place in the imaging market.
Each medtech company must consider carefully how its products and services fit its customers’ needs. Some may pursue (or continue) a category-killer approach, and dominate a narrow channel. Others may choose to be market disrupters and produce game-changing technologies. Most of today’s medtech companies have taken a blended approach, but the opportunities to partner with providers in the new outcomes-based healthcare paradigm are enticing.
A medical science liaison officer (MSLO) has long been a common, highly valued position in pharmaceutical companies, healthcare systems, and clinical research organizations. This role is designed to bridge the gap between the company’s perspective, medical science, healthcare professionals, patients, and payers. As non-medical people have less access to health plan medical policy people, the MSLO role has expanded to the medtech and biotech industries.
The orthopedic implant industry is in a continual state of development, witnessing an explosion of novel materials, designs, and applications. This process is, however, often laced with challenges and articulating joints can present the greatest number of these. By Aia Malik, Lucideon, and Chris Pickles, Ph.D.
Fused Deposition Modeling™ (FDM® ) can be used to produce an array of medical devices; however, for such devices to be practical, they must be manufactured using sterilizable materials. By David Espalin, Francisco Medina, Mireya Perez, and Ryan Wicker, The University of Texas at El Paso; and Terry Hoppe and Rob Winker, Stratasys
Manufacturing Execution System (MES) solutions have the potential to generate efficiencies, improve productivity, and simplify compliance within the medical device manufacturing industry. Used to manage production activities, this class of software typically provides the ability to schedule activity, deliver instructions to operators, synchronize manual activities with automated processes, and integrate with manufacturing computer systems to enable quality control, deviation management and effective enterprise resource planning (ERP), equipment management, and the documenting of floor activities for monitoring and reporting purposes.
The complexities of implantable medical devices such as stents, intraocular lenses, prosthetics, and catheters have increased dramatically to meet new usage demands and improve patient outcomes. The advanced features and materials used for the fabrication of these devices has proven to be a challenge. As stent-strut sizes continue to shrink and the quality of cut edges becomes more critical, the degree of precision needed is more difficult to achieve. Ultrashort-pulse lasers are on their way to becoming the tool of choice for creating these medical devices with high precision. This article discusses the technology behind ultrashort-pulse lasers and how they are used in the process of micromachining ultrafine stents, bioabsorbable stents, and many other devices.
There’s a need for better access to medical technology in the region — a forward-looking approach will help companies reach more patients.
Royal Philips announced recently an eight-year, $36 million deal to provide patient monitoring services for Medical University of South Carolina Health (MUSC Health). It's Philips' fifth, long-term, strategic deal with a North American hospital.
Stanford University scientists have developed a technology that could make the rapid urine tests frequently used in the doctors’ offices more reliable and accurate for at-home use. By addressing the most common human errors in dipstick testing — timing, volume of sample, and lighting — the technology could deliver faster test results to patients and reduce the burden on overextended medical laboratories and primary care doctors.
BALT's president, Nicolas Plowiecki, and the Board of Directors has recently hired Pascal Girin, a veteran of Medical Devices market, as the new CEO of BALT International. BALT will continue to focus on accompanying practitioners through further innovation to treat complex life-threatening conditions. The appointment of Pascal is meant to bolster the commercial and market access capabilities of Balt and lead its expansion in the US market.
Phillips-Medisize Corporation recently announced the appointment of Richard Even as General Manager of BioPharma and the medical campus in Menomonie Wisconsin. This is the latest in a series of strategic hires driven by the company’s continued growth in biopharma drug delivery devices, consumable diagnostics, and medical devices.
Engineers at the University of California San Diego have developed the first flexible wearable device capable of monitoring both biochemical and electric signals in the human body.
The U.S. Food and Drug Administration (FDA) has released draft guidance on the use of electronic health record (EHR) data by sponsors, clinical investigators, contract research organizations (CROs), institutional review boards (IRBs), and other interested parties who conduct clinical trials.
Johnson & Johnson’s (J&J) medical device business is poised for significant growth across multiple healthcare markets and in several key regions worldwide, according to senior leadership.